27th Sep 2006 09:07
BTG PLC27 September 2006 BTG appoints Peter Chambre as non-executive director London, UK, 27 September 2006: BTG plc (LSE: BGC), the medical innovationscompany, today announces the appointment of Peter Chambre as non-executivedirector on 26 September 2006. Peter was Chief Executive Officer of Cambridge Antibody Technology Group plcfrom 2002 until its recent acquisition by AstraZeneca plc. Previously he wasChief Operating Officer of Celera Genomics Group and Chief Executive of Bespakplc. He is currently a non-executive director of Spectris plc, the precisioninstrumentation and controls company. Sir Brian Fender, BTG's Chairman, commented: "I am delighted to welcome Peter toBTG's Board of Directors. He has tremendous international experience in the lifesciences sector that will be of benefit to the Company as we further develop ourbusiness." There are no further details to be disclosed in relation to paragraph 9.6.13R ofthe Financial Services Authority Listing Rules. ContactsBTG Financial DynamicsAndy Burrows, Director of Investor Relations Ben Atwell+44 (0)20 7575 1741 +44 (0)20 7831 3113Christine Soden, Chief Financial Officer+44 (0)20 7575 1591 About BTG BTG in-licenses, develops and commercialises pharmaceuticals and other medicaltechnologies. With a substantial and growing revenue stream of royalties andmilestone payments from out-licensed products, BTG continues to strengthen itspipeline of preclinical and clinical development programmes. Active in thefields of oncology, diseases of ageing, neuroscience, drug repositioning andmedical devices, BTG works from its offices in London, Philadelphia and Osakawith a global partner network of healthcare companies and researchorganisations. For further information, visit: www.btgplc.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
BTG